OPKO Health (NASDAQ:OPK) Stock Price Up 3.1% - Should You Buy?

OPKO Health, Inc. (NASDAQ:OPK - Get Free Report)'s share price shot up 3.1% on Tuesday . The company traded as high as $1.81 and last traded at $1.81. 1,335,916 shares traded hands during mid-day trading, a decline of 71% from the average session volume of 4,548,040 shares. The stock had previously closed at $1.75.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on OPK shares. StockNews.com upgraded shares of OPKO Health from a "sell" rating to a "hold" rating in a research note on Monday, March 3rd. HC Wainwright restated a "buy" rating and issued a $3.00 price objective on shares of OPKO Health in a research note on Monday, March 3rd. Finally, Barrington Research restated an "outperform" rating and issued a $2.25 price objective on shares of OPKO Health in a research note on Friday, February 28th.

OPKO Health Trading Up 0.5 %

The company has a market cap of $1.28 billion, a price-to-earnings ratio of -10.00 and a beta of 1.70. The company has a debt-to-equity ratio of 0.30, a quick ratio of 2.69 and a current ratio of 2.97. The business's 50 day moving average price is $1.59 and its 200-day moving average price is $1.56.

OPKO Health (NASDAQ:OPK - Get Free Report) last announced its earnings results on Thursday, February 27th. The biotechnology company reported $0.01 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.08) by $0.09. The business had revenue of $183.60 million during the quarter, compared to analysts' expectations of $155.42 million. OPKO Health had a negative net margin of 18.65% and a negative return on equity of 9.76%. On average, research analysts forecast that OPKO Health, Inc. will post -0.25 EPS for the current year.

Remove Ads

Insider Buying and Selling

In other news, CEO Phillip Md Et Al Frost bought 500,000 shares of the company's stock in a transaction that occurred on Wednesday, December 11th. The stock was acquired at an average price of $1.56 per share, for a total transaction of $780,000.00. Following the transaction, the chief executive officer now directly owns 212,411,477 shares of the company's stock, valued at $331,361,904.12. This trade represents a 0.24 % increase in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Insiders bought 1,389,971 shares of company stock worth $2,124,442 in the last quarter. 47.26% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On OPKO Health

Institutional investors have recently modified their holdings of the stock. Rubric Capital Management LP raised its stake in shares of OPKO Health by 9.6% in the third quarter. Rubric Capital Management LP now owns 48,706,640 shares of the biotechnology company's stock worth $72,573,000 after acquiring an additional 4,284,336 shares during the last quarter. Barclays PLC raised its stake in shares of OPKO Health by 154.5% in the third quarter. Barclays PLC now owns 543,336 shares of the biotechnology company's stock worth $810,000 after acquiring an additional 329,870 shares during the last quarter. BNP Paribas Financial Markets raised its stake in shares of OPKO Health by 736.7% in the third quarter. BNP Paribas Financial Markets now owns 246,967 shares of the biotechnology company's stock worth $368,000 after acquiring an additional 217,450 shares during the last quarter. Intech Investment Management LLC bought a new position in shares of OPKO Health in the third quarter worth about $190,000. Finally, FMR LLC raised its stake in shares of OPKO Health by 103.6% in the third quarter. FMR LLC now owns 21,795 shares of the biotechnology company's stock worth $32,000 after acquiring an additional 11,089 shares during the last quarter. 64.63% of the stock is owned by institutional investors.

About OPKO Health

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.